Background-Chronic inflammation represents an essential feature of the atherosclerotic process. Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), an enzyme mainly produced by monocytes/macrophages, generates potent proinflammatory products. Methods and Results-Plasma concentrations of Lp-PLA 2 were determined by ELISA in 934 apparently healthy men aged 45 to 64 years sampled from the general population in 1984 and followed up until 1998. During this period, 97 men experienced a coronary event diagnosed according to the MONICA (MONItoring of trends and determinants in CArdiovascular disease) protocol. Baseline levels of Lp-PLA 2 were higher in subjects who experienced an event than in event-free subjects (295Ϯ113 versus 263Ϯ79 ng/mL, PϽ0.01). Lp-PLA 2 was positively correlated with total cholesterol (Rϭ0.30, PϽ0.0001) and age (Rϭ0.12, Pϭ0.001), was only slightly correlated with HDL cholesterol (Rϭ0.09, Pϭ0.005) and C-reactive protein Rϭ0.06, Pϭ0.06), but was not correlated with body mass index or blood pressure. In a Cox model, a 1-SD increase in Lp-PLA 2 was associated with risk of future coronary events (hazard ratio [HR] 1.37, 95% CI 1.16 to 1.62). After controlling for potential confounders, the HR was attenuated but remained statistically significant (HR 1.23, 95% CI 1.02 to 1.47). Further inclusion of C-reactive protein in the model did not appreciably affect its predictive ability (HR 1.21, 95% CI 1.01 to 1.45). Conclusions-Elevated levels of Lp-PLA 2 appeared to be predictive of future coronary events in apparently healthy middle-aged men with moderately elevated total cholesterol, independent of CRP. This suggests that Lp-PLA 2 and CRP may be additive in their ability to predict risk of coronary heart disease.
A lthough most patients with coronary heart disease (CHD) do have at least 1 major risk factor, the same can be said for most middle-aged and elderly subjects without CHD. 1, 2 Thus, classic risk factors cannot account for all incident coronary events, and there may be a substantial number of subjects without elevated lipoprotein concentrations who have the disease. 3, 4 Even following current recommendations to use global risk assessment for risk stratification in asymptomatic subjects leaves a large proportion of the population at intermediate risk, 5 where no established strategies are available. Such an obvious gap has fueled the search for additional diagnostic tools. Because inflammation plays an important role in atherogenesis and its clinical complications, in recent years, a large number of biomarkers of inflammation have been investigated in prospective studies and have been found to be associated with cardiovascular events. 6 For a number of reasons, the most promising marker at present seems to be C-reactive protein (CRP). 7 Indeed, recently, it could be shown that adding CRP to the Framingham risk score resulted in improved risk prediction, in particular in those in the intermediate range. 8 However, increasing evidence suggests that a variety of inflammatory molecules are involved in the atherothrombotic process, 9 and not all of them may reflect the same pathophysiology, thus raising the interesting question of whether or not the combination of different markers may further improve risk prediction.
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an enzyme that may directly promote atherogenesis by generating potent proinflammatory and proatherogenic products, such as lysophosphatidylcholine and oxidized free fatty acids from oxidation of LDL, 10 -12 an important step in atherogenesis. Lp-PLA 2 is produced mainly by the characteristic cells of the atherosclerotic plaque, namely, monocytes/macrophages, T lymphocytes, and mast cells. 13, 14 Furthermore, Lp-PLA 2 has been detected in both human and rabbit atherosclerotic lesions. 15 Experimental studies in Watanabe heritable hyperlipidemic rabbits have demonstrated that inhibition of Lp-PLA 2 leads to the reduction of atherosclerotic lesion formation. 16 In the bloodstream, two thirds of the Lp-PLA 2 plasma isoform circulates primarily bound to LDL; the other third is distributed between HDL and VLDL. 17 We sought to investigate simultaneously the association between plasma concentrations of Lp-PLA 2, CRP, and longterm risk of CHD in initially healthy middle-aged men from the general population in Augsburg, Southern Germany.
Methods

Study Design, Population, and Follow-Up
The population-based MONICA (MONItoring of trends and determinants in CArdiovascular disease) Augsburg survey, conducted in 1984/1985, was used as the database. The MONICA Augsburg project was part of the multinational World Health Organization MONICA project. 18, 19 Briefly, 4022 of the 5069 eligible individuals aged 25 to 64 years initially sampled at random from a study population of 282 279 inhabitants of a mixed urban/rural area participated in the first survey (response rate 79.3%). The present report is based on all 1074 men aged 45 to 64 years. Of these subjects, 140 men were not included in the analyses because of a previous myocardial infarction (MI), missing values for CRP or Lp-PLA 2 , or control variables. Thus, a total of 934 men aged 45 to 64 years had data on all variables studied.
In a follow-up study in 1998, the vital status was assessed for all sampled persons of the first MONICA survey in 1984. During the 14-year observation period, 209 men aged 45 to 64 years at baseline had died, and vital status could not be assessed for 1 man. The outcome variable was a combination of incident fatal or nonfatal acute MI and sudden cardiac death. They were identified through the MONICA/KORA (KOoperative Gesundheitsforschung in der Region Augsburg) coronary event registry of the 25-to 74-year-old study population and censored at the 75th year of age. 20 According to the MONICA manual, 19 the diagnosis of a major nonfatal MI event was based on symptoms, cardiac enzymes, and typical ECG changes. Deaths from cardiovascular causes were validated by autopsy reports, death certificates, chart review, and information from the last treating physician.
Survey Methods
All participants completed a standardized questionnaire, including medical history, lifestyle, and drug use history. Blood pressure, body height (m) and body weight (kg), body mass index (BMI, m/kg 2 ), smoking behavior, and alcohol consumption (g/d) were determined as described elsewhere. 21 Leisure-time physical activity was assessed on a 4-level graded scale for winter and summer. 22 The number of education years was calculated on the basis of the highest level of formal education completed.
Laboratory Procedures
A nonfasting venous blood sample was collected from all participants in a supine resting position. Samples for measurement of CRP and Lp-PLA 2 were stored at Ϫ70°C until analysis. Serum CRP concentrations were measured with a high-sensitivity (hs) immunoradiometric assay (range 0.05 to 10 mg/L) as described previously. 23 The coefficient of variation for repeated measurements was 12% over all ranges. Plasma levels of Lp-PLA 2 were determined with a commercial Lp-PLA 2 -ELISA kit (PLAC test; supplied by diaDexus Inc, South San Francisco, Calif). 12 The lower detection limit of Lp-PLA 2 in this assay is Ϸ2 ng/mL. The interassay coefficient of variation was 9.6%. Total serum cholesterol (TC) and HDL cholesterol (HDL-C) were measured by routine enzymatic methods. Corresponding coefficients of variation were between 1 and 3% for TC, and between 3 and 4% for HDL-C. All analyses were run in a blinded fashion.
Statistical Analysis
Means or proportions for baseline demographic and clinical characteristics were computed for men with and without an incident coronary event. The distribution of CRP concentrations and the TC/HDL-C ratio were markedly skewed and were therefore logtransformed. Differences between continuous variables were tested for statistical significance by means of t tests, and proportions were tested by 2 test. We assessed associations among variables with use of Pearson's correlation coefficient. Cox proportional hazards analysis was used to assess the independent risk for the occurrence of a first coronary event for an increase of 1 SD of CRP and Lp-PLA 2 .
Results are presented as hazard ratios (HRs) together with their 95% CIs. First, crude HRs were calculated. Results were then adjusted for age (continuous), regular smoking (yes/no), and history of diabetes (yes/no) and were further adjusted for the TC/HDL-C ratio (continuous), BMI (continuous), systolic blood pressure (continuous), alcohol consumption (0 g/d, 0.1 to 39.9 g/d, Ն40 g/d), physical activity (inactive/active), and education years (Ͻ12 or Ն12 years) in all other models. Finally, the potential additive effect of CRP and Lp-PLA 2 was evaluated. For this purpose, high CRP was defined as Ͼ3.0 mg/L, and high Lp-PLA 2 was defined as Ն290.8 ng/mL (upper tertile cutpoint). A similar stepwise analytical procedure was chosen. Probability values are based on the Wald statistic. Significance tests are 2 tailed, and probability values Ͻ0.05 were considered statistically significant. All analyses were performed with the Statistical Analysis System (version 8.2, SAS Institute Inc).
Results
Baseline Characteristics
During an average follow-up of 14 years, a total of 97 fatal and nonfatal coronary events, including sudden cardiac death, occurred. Men with an acute event were significantly older, had higher TC and HDL-C, and had a higher TC/HDL-C ratio. They were more frequently smokers, were less frequently physically active, and had a higher prevalence of diabetes. Concentrations of both Lp-PLA 2 and CRP were considerably higher than in those free of an event during follow-up (Table 1) .
Correlation Between Lp-PLA 2 , CRP, and Other Risk Factors
Lp-PLA 2 was positively correlated with age (Rϭ0.12, Pϭ0.0001) and TC (Rϭ0.30, PϽ0.0001). It was only slightly correlated with HDL-C (Rϭ0.09, Pϭ0.005) but was not correlated with smoking, BMI, or systolic blood pressure. The latter, however, were correlated with CRP (Table 2) . Lp-PLA 2 concentration was only marginally correlated with CRP (Rϭ0.06, Pϭ0.06).
Lp-PLA 2 , CRP, and Risk of a First Coronary Event
In a model containing only Lp-PLA 2 , a 1-SD increase in the marker was associated with a 37% increase in coronary risk in unadjusted analyses (HR 1.37, 95% CI 1.16 to 1.62; Pϭ0.0002). Multivariable adjustment for traditional risk factors reduced the HR to 1.23 (95% CI 1.02 to 1.47), which was still statistically significant (Table 3) . Similar analyses for CRP resulted in an HR of 1.57 (95% CI 1.30 to 1.91) in unadjusted analyses, which was reduced to 1.28 (95% CI 1.03 to 1.60) after multivariable adjustments had been made (Table 3) .
Combined Analysis of Inflammatory Markers and Risk of a First Coronary Event
When both markers were simultaneously assessed in the same model, they still independently predicted future coronary events in unadjusted analyses, with only slightly reduced HRs for Lp-PLA 2 (1.35, 95% CI 1.14 to 1.60) and CRP (1.55, 95% CI 1.28 to 1.89). This held true in further analyses that took into account a variety of traditional risk factors, in which the decrease of the HR for CRP was somewhat stronger (1.27, 95% CI 1.01 to 1.59) than for the HR for Lp-PLA 2 (1.21, 95% CI 1.01 to 1.45; Table 3 ).
Finally, we looked at the potential additive effect of both markers for risk prediction. For this purpose, we defined high CRP according to a recent American Heart Association/ Centers for Disease Control and Prevention consensus document 7 as Ͼ3.0 mg/L. For Lp-PLA 2 , the upper tertile cutpoint (290.8 ng/mL) was used. Again, a similar stepwise analytical procedure was chosen, with examination first of the unadjusted relationship, then with adjustment for age, diabetes, and smoking, and finally, with additional adjustment for the remainder of the potential confounders. The Figure shows that the combination of both elevated Lp-PLA 2 and elevated CRP was consistently associated with a statistically significantly increased risk for future coronary events and was superior to either elevated marker alone in predicting risk, with an HR of 1.93 (95% CI 1.09 to 3.40) compared with both markers not being increased (referent) in the fully adjusted model.
Discussion
In this prospective cohort study, we directly compared the relative risk for future coronary events associated with elevated Lp-PLA 2 and with elevated CRP concentrations. 
Koenig et al Lp-PLA 2 and Risk of Coronary Events
Basically, both markers were elevated in those who subsequently developed an event compared with those who did not. In separate models, both variables were strongly and independently related to a first-ever event, even after controlling for a variety of potential confounders, which included the TC/HDL-C ratio as the strongest lipoprotein variable. In a model that contained both markers, again, each was strongly and independently associated with future adverse events after multivariable adjustments. Finally, the present results show an additive effect of both markers on risk prediction.
Prospective Evidence for the Association Between Lp-PLA 2 and CHD From Other Studies
To date, 3 prospective studies have reported on the association between elevated Lp-PLA 2 and future cardiovascular risk in different populations. Initial evidence for such an association came from the West of Scotland Coronary Prevention Study (WOSCOPS) 24 in hyperlipidemic, middle-aged men followed up for 5 years. In that study, a 1-SD increase in Lp-PLA 2 was associated with an 18% increase in risk in multivariable analysis, even after controlling for other markers of inflammation, compared with a 21% increased risk for coronary events in the present study. These results are very similar despite the fact that the 2 study populations were clearly different in both their TC level, which was 272 mg/dL in WOSCOPS and 245 mg/dL in MONICA/KORA, and their HDL-C level, which was 44 and 51.3 mg/dL, respectively. Other characteristics were comparable, except for BMI, which was slightly higher in Augsburg. In addition, we studied a full cohort sampled from the general population with a much longer follow-up of 14 years compared with a case-cohort study with a follow-up of 5 years within WOSCOPS, a primary prevention trial to evaluate the effect of pravastatin on coronary events. Thus, the present data show for the first time that Lp-PLA 2 is able to predict risk in the long term. The predictive role of Lp-PLA 2 has been assessed in the Women's Health Study (WHS), a low-risk population for cardiovascular diseases. 25 Baseline concentrations of Lp-PLA 2 were increased among women who subsequently developed cardiovascular events (including 74 cases of MI and 49 with stroke) compared with those who remained free of vascular disease (mean 1.20 versus 1.05 mg/L, respectively; Pϭ0.016). However, the relative risk in the top quartile compared with the bottom quartile was 1.73 (95% CI 0.87 to 3.44) and thus statistically nonsignificant and decreased further to 1.17 (95% CI 0.45 to 3.05) after adjustment for various risk factors. This lack of association is in contrast to findings from WOSCOPS and the present cohort study and may be attributable to gender differences of Lp-PLA 2 , because only women participated in WHS compared with WOSCOPS and the present study in men only. Indeed, several studies 26 -28 have already reported lower concentrations of Lp-PLA 2 in women than in men.
The third prospective study has recently been published based on data from the Atherosclerosis Risk in Communities (ARIC) study. 29 A case-cohort design was chosen, and 608 men and women with incident CHD were compared with 740 controls from a cohort random sample and followed up for 6 to 8 years. Again, Lp-PLA 2 concentrations were higher in cases than in controls. In age-and gender-adjusted analysis, Lp-PLA 2 was associated with increased risk (HR in the top tertile compared with the bottom tertile was 1.78; 95% CI 1.33 to 2.38), but statistical significance was lost after multivariable adjustments. In contrast, CRP was predictive in overall analysis even after multivariable adjustments (HR 1.72; 95% CI 1.24 to 2.39 comparing those with CRP Ͼ3.0 mg/L with those with CRP Ͻ1.0 mg/L). However, the authors found a significant interaction between Lp-PLA 2 and LDL cholesterol (Ͻ130 and Ն130 mg/dL). In subjects with low LDL cholesterol, Lp-PLA 2 significantly and independently predicted CHD (HR 2.08, 95% CI 1.20 to 3.62). Individuals with high Lp-PLA 2 (Ն422 g/L) and high CRP (Ͼ3 mg/L) in this subgroup exhibited the largest risk for CHD (HR 2.95, 95% CI 1.47 to 5.94). Compared with the present study, ARIC had included females, blacks, and more subjects with diabetes; participants also had a higher BMI but lower blood pressures and TC and similar HDL-C values. Despite these differences, Lp-PLA 2 and CRP were found to be complementary predictors for individuals at high risk in both studies, although in ARIC, this was true only in those with low LDL cholesterol.
Correlations Between Lp-PLA 2 and Other Risk Factors
In all 4 studies, a strong correlation was seen between Lp-PLA 2 and either TC or LDL cholesterol. Discrepant findings have been reported for HDL-C, with inverse correlations in WHS and ARIC and small positive correlations in WOSCOPS and MONICA/KORA. These differences cannot be explained so far. Interestingly, in all studies, correlations with other traditional risk factors were negligible, and in particular, no relevant correlation was seen with CRP. In contrast, CRP has been shown to correlate with most traditional risk factors, the most pronounced correlations being seen with smoking and BMI. 24 Thus, compared with CRP, Lp-PLA 2 has the advantage of being only minimally correlated with other risk factors, which may represent an important advantage for the clinical application of the test.
Strengths and Limitations of the Study
The present study has several strengths. In contrast to WOSCOPS and the WHS, which both used case-control designs, in the present study, a complete cohort, drawn randomly from the general population, has been investigated. Although ARIC also represents a population-based sample, the analysis was done with a case-cohort design. We used only hard coronary end points in our analysis, whereas in the other studies, either revascularization procedures or stroke were included in addition to fatal and nonfatal MI. The considerably longer follow-up of 14 years extends the observations reported from these other studies regarding the time frame within which Lp-PLA 2 might be a useful predictor. The average TC level in the present study, which was lower than in WOSCOPS but higher than in ARIC, finally closes the gap and suggests that Lp-PLA 2 may predict coronary events across all levels of TC.
The present study has several limitations that need to be mentioned. The number of events was rather small, so the power of the study is limited. Also, LDL cholesterol had not been measured for logistical reasons, and therefore, we could not specifically address the question of whether Lp-PLA 2 might be particularly useful as a predictor in those with low LDL cholesterol.
Despite these limitations, our results provide strong evidence for an independent and clinically relevant relationship between elevated concentrations of Lp-PLA 2 and subsequent risk of CHD in apparently healthy middle-aged men from the general population and thus lend further support to the hypothesis that Lp-PLA 2 may be considered as a novel risk marker for CHD. In addition, our results suggest that Lp-PLA 2 and CRP may be complementary in identifying highrisk subjects, and therefore, the combination of both markers may further improve risk assessment. Moreover, because specific inhibitors of Lp-PLA 2 are currently under development, 16, 30 lowering of this enzyme in plasma and/or the vessel wall would represent a novel, promising tool for the treatment of atherosclerosis and thus may open a new avenue to combat this still widespread disease.
